| abstract |
The present invention relates to a HMG CoA Reductase inhibiting composition with improved bioavailability. The present invention also relates to a method for preparation of such composition and to the competitive inhibition of HMG CoA Reductase using such composition. The active ingredients are present in a rapidly dissolvable and more solubilized state, thereby enabling sustained and complete solubilization, more rapid dissolution upon administration to a patient, improved absorption and/or bioavailability and also increased flexibility in terms of providing the active ingredient and being capable of administration in the form of a solution, suspension, solid dispersion, solid solution or semi-solid formulation. |